February 6, 2018 U.S., European Biosimilar Approval Activity in 2017
February 1, 2018 Patent dance remains on point
December 8, 2017 Mixed Results as IPR Petitions for Biosimilars Soar
November 1, 2017 Fed. Circ. Clarifies Law For Functional Antibody Claims
October 25, 2017 The Supreme Court’s interpretation of the biosimilars statute and the value of certainty
October 5, 2017 A New Strain Of Inequitable Conduct Litigation
June 15, 2017 High Court Interprets The Biosimilars Statute — What Now?
June 6, 2017 Update on Biosimilar Approvals and Pending Applications in Europe and the U.S.
April 27, 2016 A Breakthrough Technology is Caught in an Epic Patent Battle
March 16, 2016 Biosimilar Makers Turn To IPRs Despite Mixed Results
December 9, 2015 All Camps Agree: Memorable Biosimilar Names are a Must
October 27, 2015 TPP Biologics Exclusivity Period Maintains The Status Quo
June 2015 Biobetters: The Advantages and Challenges of Being Better
June 2015 New Targets in the Crosshairs: A forum to invalidate patents is now being used on biotech firms
April 2015 The Value of Being Highly Similar: First U.S. Biosimilar
October 2014 If High Court Reverses Teva, Litigation Costs May Increase
February 2012 FDA Issues Draft Guidelines for Biosimilars
June 2011 Supreme Court Decision: Board of Trustees of the Leland Stanford Junior University v. Roche Molecular Systems, Inc.